Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 7:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 85 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Certolizumab pegol (CDP870) Clear all
Completed Phase 3 Interventional Results available

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

NCT01374971
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol (CZP), Arthroscopic synovial tissue biopsy
Drug · Procedure
Lead sponsor
Nathan Wei, MD, FACP, FACR:
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 10, 2026, 7:30 PM EDT
Completed No phase listed Observational

Novel Imaging Markers for Rheumatoid Arthritis

NCT01773681
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cimzia, Magnetic Resonance Imaging (MRI), High-resolution peripheral quantitative computed tomography (HR-pQCT)
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

NCT02505542
View directory record Official record
Conditions
Axial Spondyloarthrithis, Ankylosing Spondylitis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 10, 2026, 7:30 PM EDT
Terminated Phase 3 Interventional Results available

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol 400 mg, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects

NCT02806219
View directory record Official record
Conditions
Healthy
Interventions
Prefilled syringe (PFS), e-Device
Device
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Not applicable Interventional

Study to Look at Benefit of Surgical Drainage Before Beginning Medical Therapy for Crohns Perianal Fistulas

NCT01145365
View directory record Official record
Conditions
Crohns Disease, Fistula, Abscess
Interventions
Exam under anesthesia (EUA)
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

NCT00175877
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
19
States / cities
Huntsville, Alabama • San Diego, California • Danbury, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 10, 2026, 7:30 PM EDT
Recruiting No phase listed Observational

CHronic Nonbacterial Osteomyelitis International Registry

NCT04725422
View directory record Official record
Conditions
Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
Interventions
Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

NCT01521923
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol + Methotrexate (MTX), Placebo + Methotrexate (MTX)
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects

NCT01255761
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol (CZP)
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

NCT00753454
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 10, 2026, 7:30 PM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

NCT00356408
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Montgomery, Alabama • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 2 Interventional Results available

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

NCT01190410
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
6 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
7
States / cities
Orange, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 4 Interventional

Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis

NCT04891640
View directory record Official record
Conditions
Juvenile Spondyloarthritis
Interventions
Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 21 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 7:30 PM EDT
Recruiting Phase 2 Interventional

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

NCT04991025
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III
Interventions
Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Certolizumab, Nivolumab, Paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 10, 2026, 7:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

NCT03553472
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 49 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

NCT02552212
View directory record Official record
Conditions
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 10, 2026, 7:30 PM EDT
Completed No phase listed Observational

Cytokines and Genes in Therapeutic Response in Crohn's Disease

NCT03266471
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Baseline blood sample, Baseline intestinal biopsies, Crohn's disease activity index (CDAI), Post treatment blood sample, Post treatment intestinal biopsies, Baseline stool sample, Post treatment stool sample
Diagnostic Test · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 4 Interventional

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions
Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
Drug
Lead sponsor
Jeffrey Curtis
Other
Eligibility
18 Years to 85 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

NCT00717236
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol (CZP), Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
101
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 10, 2026, 7:30 PM EDT
Completed Phase 3 Interventional

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

NCT00152386
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol (CDP870)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 10, 2026, 7:30 PM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 10, 2026, 7:30 PM EDT